Nuveen LLC acquired a new position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 507,527 shares of the company's stock, valued at approximately $807,000. Nuveen LLC owned about 0.71% of Zentalis Pharmaceuticals as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in ZNTL. Deutsche Bank AG increased its stake in shares of Zentalis Pharmaceuticals by 34.1% in the fourth quarter. Deutsche Bank AG now owns 42,804 shares of the company's stock valued at $130,000 after buying an additional 10,873 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in Zentalis Pharmaceuticals by 17.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 234,071 shares of the company's stock valued at $372,000 after acquiring an additional 33,958 shares during the period. BNP Paribas Financial Markets acquired a new position in Zentalis Pharmaceuticals in the 4th quarter valued at approximately $534,000. Millennium Management LLC raised its stake in shares of Zentalis Pharmaceuticals by 8.1% during the fourth quarter. Millennium Management LLC now owns 957,563 shares of the company's stock valued at $2,901,000 after acquiring an additional 71,477 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at $68,000.
Zentalis Pharmaceuticals Stock Performance
Shares of NASDAQ:ZNTL traded down $0.02 during midday trading on Friday, reaching $1.75. The company's stock had a trading volume of 422,761 shares, compared to its average volume of 808,381. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $1.01 and a fifty-two week high of $5.44. The firm has a 50 day moving average price of $1.49 and a two-hundred day moving average price of $1.49. The firm has a market capitalization of $126.25 million, a price-to-earnings ratio of -0.77 and a beta of 1.76.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.19. As a group, research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on the stock. HC Wainwright raised shares of Zentalis Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 7th. Wedbush reiterated a "neutral" rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. Wells Fargo & Company lowered their price objective on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Finally, Wall Street Zen raised Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.20.
Get Our Latest Research Report on ZNTL
Zentalis Pharmaceuticals Company Profile
(
Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Featured Stories
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
